[1] J. Shepherd, Am. J. Cardiol., 1998, 82, 57T-59T
[2] D. Williams, J. Feely, Clin. Pharmacokinet., 2002, 41, 343-370
[3] J.W. Jukema, A.H. Zeinderman, A.J. Van Boven, J.H. Reiber, A. Van Der Laarse, K.I. Lie,
A.V. Bruschke,
Arterioscler Thromb. Vasc. Biol.,
1996, 16, 425-430
[4] A.G. Olsson, F. McTaggart, A. Raza, Cardiovasc. Drug Rev., 2002, 20, 303-328.
[5] J.W. Blasetto, E.A. Stein, W.V. Brown, R. Chitra, A. Raza, Am. J. Cardiol., 2003, 91, 3C-10C
[6] P.D. Martin, A.L. Dane, O.M. Nwose, D.W. Schneck, M.J. Warwick, J.Clin. Pharmacol., 2002, 42, 1116-1121
[7] P.D. Martin, P.D. Mitchell, D.W. Schneck, Br. J. Clin. Pharmacol., 2002, 54, 472-477
[8] P.D. Martin, M.J. Warwick, A.L. Dane, C. Brindley, T. Short, Clin. Ther., 2003, 25, 2553-2563
[9] J.W. Jukema, J.W. Van Der Hoorn, Expert Opin. Pharmacother., 2004, 5, 459-468
[10] B.Y. Kang, W. Wang, P. Palade, S.G. Sharma, J.L. Mehta, J. Cardiovas. Pharmacol., 2009, 54, 327-334
[11] N. Karadas Bakirhan, M. Gumustas, B. Uslu, S.A. Ozkan, Ionics 2016, 22, 277-288
[12] D. Tajane, A.M. Raurale, P.D. Bharande, A.N. Mali, A.V. Gadkari, V.R. Bhosale, J. Chem. Pharm. Res., 2012, 4, 2789-2794
[13] S.K. Banerjee, N.M. Vasava, Bull. Pharm. Res., 2013, 3, 29-33
[14]
G.B. El-Hefnawey,
I.S. El-Hallag,
E.M. Ghoneim,
M.M. Ghoneim,
J. Pharm. Biomed. Anal., 2004, 34, 75-86
[15] P. Corti, G. Corbini, P. Gratteri, S. Furlanetto, S. Pinzauti, Int. J. Pharm., 1994, 11, 83-87
[16] A. Radi, T. Elmogy, IL Farmaco, 2005, 60, 43-46
[17] United States Pharmacopeia 32 (USP 32) Revision; United States Pharmacopeia Convention, Rockville, MD, USA, 2009
[18] I.C.H, Stability testing of new drug substances and products, Q1A(R2). International Conference on Harmonization; IFPMA, Geneva, 2003
[19] E. Laviron, L. Roullier, C. Degrand, J. Electroanal. Chem., 1980, 112, 11-23
[20] B. Yilmaz, D. Ekinci, Rev. Anal. Chem., 2011, 30, 187-193
[21] E. Arkan, Z. Karimi, M. Shamsipur, R. Saber, J. Reports Pharmaceutical Sci., 2014, 3, 99-107
[22] Z.Z. Stoiljkovic, M.L. Avramov Ivic, S.D. Petrovic, D.Z. Mijin, S.I. Stevanovic, U.C. Lacnjevac, A.D. Marinkovic, Int. J. Electrochem. Sci., 2012, 7, 2288-2303
[23] A.A. Ramadan, H. Mandil, N. Ghazal, Int. J. Pharmacy Pharmaceutical Sci., 2014, 6, 128-133
[24] S. Altınoz, B. Uyar, Anal. Methods, 2013, 5, 5709-5716
[25] T.A. Silva, H. Zanin, F.C. Vicentini, E.J. Corat, O. Fatibello-Filho, Sensors Act. B Chemical, 2015, 218, 51-59
[26] M. Ashfaq, T. Akhtar, G. Mustafa, M. Danish, S.N. Razzaq, M.F. Nazar, Braz. J. Pharm. Sci., 2014, 50, 629-638
[27] US DHHS. FDA and CDER. Guidance for industry: bioanalytical method validation. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001
[28] Guideline on bioanalytical method validation. Science and Medicinal Health. European Medicines Agency (EMEA). EMEA/CHMP/EWP/192217/2009, 2011
[29] ICH, Topic Q2A validation of analytical procedures, methodology, PMP/ICH/281/95.
[30] C.M Riley , T.W. Rosanske, Development and validation of analytical methods. Elsevier; New York, 1996
[31] M.E. Swartz, I.S. Krull, Analytical method development and validation. Marcel Dekker, New York, 1997
[32] The United States Pharmacopoeia. 24th revision, Easton, Rand Mc Nally Taunton, 2000.
)
)